May 10, 2021 8:00am EDT Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
Apr 26, 2021 8:00am EDT Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Apr 10, 2021 2:15pm EDT Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
Mar 30, 2021 7:00am EDT Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update
Mar 25, 2021 8:00am EDT Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA® (tucatinib) in Gastric Cancer, and Strategic Equity Investment by Seagen
Mar 23, 2021 8:00am EDT Pieris Pharmaceuticals to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 30, 2021
Feb 23, 2021 8:00am EST Pieris Pharmaceuticals to Participate in the Cowen 41st Annual Health Care Conference
Nov 04, 2020 7:00am EST Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
